The U.S. Food and Drug Administration said on Tuesday it had approved the first generic version of Xyrem, Jazz Pharmaceuticals Plc's drug to treat patients with a medical condition that causes excessive daytime sleepiness. (http://bit.ly/2jHzIS9)
Continue Reading Below
Jazz Pharma's shares were down 4.8 percent at $110 in extended trading.
(Reporting by Divya Grover in Bengaluru; Editing by Maju Samuel)